Bluejay Diagnostics (NASDAQ:BJDX) Rating Lowered to “Sell” at Wall Street Zen

Bluejay Diagnostics (NASDAQ:BJDX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Bluejay Diagnostics Stock Performance

NASDAQ BJDX opened at $0.90 on Friday. Bluejay Diagnostics has a 1-year low of $0.83 and a 1-year high of $16.68. The stock has a 50-day moving average of $1.34 and a 200-day moving average of $2.03. The firm has a market cap of $4.02 million, a PE ratio of -0.13 and a beta of 0.89.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3,520.00) by $3,518.88.

Insider Activity

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt purchased 64,047 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was bought at an average cost of $1.51 per share, for a total transaction of $96,710.97. Following the purchase, the insider directly owned 126,993 shares in the company, valued at $191,759.43. The trade was a 101.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. 18.47% of the stock is owned by institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.